Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $107.0 million.

  • Century Therapeutics' Non-Current Assets fell 4140.02% to $107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.7 million, marking a year-over-year decrease of 2627.77%. This contributed to the annual value of $159.2 million for FY2024, which is 1335.46% down from last year.
  • As of Q3 2025, Century Therapeutics' Non-Current Assets stood at $107.0 million, which was down 4140.02% from $124.5 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Non-Current Assets ranged from a high of $255.9 million in Q2 2023 and a low of $107.0 million during Q3 2025
  • For the 4-year period, Century Therapeutics' Non-Current Assets averaged around $173.0 million, with its median value being $166.8 million (2022).
  • Per our database at Business Quant, Century Therapeutics' Non-Current Assets skyrocketed by 7197.21% in 2023 and then plummeted by 4152.97% in 2025.
  • Over the past 4 years, Century Therapeutics' Non-Current Assets (Quarter) stood at $166.8 million in 2022, then grew by 10.11% to $183.7 million in 2023, then fell by 13.35% to $159.2 million in 2024, then plummeted by 32.77% to $107.0 million in 2025.
  • Its last three reported values are $107.0 million in Q3 2025, $124.5 million for Q2 2025, and $146.0 million during Q1 2025.